Recombinant human epidermal growth factor on oral mucositis induced by intensive chemotherapy with stem cell transplantation
Kyung Im Kim(Korea University), Byoung Kook Kim(Seoul National University), Sung‐Soo Yoon(Seoul National University), Hyun Jung Lee(Yonsei University), Soo‐Mee Bang(Seoul National University), Inho Kim(Seoul National University), Jong Seok Lee(Korea Institute of Ocean Science and Technology), Byung‐Su Kim(Hallym University Dongtan Sacred Heart Hospital), Seonyang Park(Seoul National University), Ji‐Won Kim(Kyungpook National University), Jung Mi Oh(Seoul National University)
Cited by 23
Related Papers
Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial
|The Lancet Oncology|2020|401
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study
|The Lancet|2023|194
Low‐Dose Botulinum Toxin Type A for the Treatment of Refractory Piriformis Syndrome
|Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy|2007|73
Current globalization of drug interventional clinical trials: characteristics and associated factors, 2011–2013
|Trials|2017|50
Clinical and genetic factors affecting tacrolimus trough levels and drug-related outcomes in Korean kidney transplant recipients
|European Journal of Clinical Pharmacology|2011|47